News & Updates

Real-world data in Japan: 1L/2L palbociclib-ET effective in HR-positive/HER2-negative advanced breast cancer
Real-world data in Japan: 1L/2L palbociclib-ET effective in HR-positive/HER2-negative advanced breast cancer
13 May 2024